Results 251 to 258 of about 64,429 (258)

Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.

Journal of the American College of Cardiology, 2014
Jose Banchs, Mary E Putt
exaly  

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

Annals of Oncology, 2004
Stephen Ackland, Armando Santoro, M Inbar   +2 more
exaly  

Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity.

Journal of the American College of Cardiology, 2019
Ana Martín-García, Rodrigo Fernandez-Jimenez, Carlos Galán-Arriola   +2 more
exaly  

Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine

Cancer Chemotherapy and Pharmacology, 2006
Søren Astrup Jensen
exaly  

Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy

Circulation, 2015
Ines Tedeschi, Fabrizio Veglia
exaly  

Anthracycline cardiotoxicity

Expert Opinion on Drug Safety, 2006
Charles Swanton, Robin L Jones
exaly  

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate

Annals of Oncology, 2008
exaly  

Navigating cancer therapy induced cardiotoxicity: From pathophysiology to treatment innovations

Advanced Drug Delivery Reviews
Brian C Jensen, Juliane Nguyen, Jessica Tetterton   +2 more
exaly